David Ludvigson

Mr Ludvigson is currently a director (was formerly President & CEO) af Nanomix, a point-of-care diagnostic medical device company. David is a financial and operating executive with over 35 years of experience in life sciences and technology companies including Biogen (formerly IDEC Pharmaceuticals), Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. His experience over 15 years in the diagnostics arena has led new product efforts from concept to market launch. David has conducted many strategic transactions including multiple acquisitions, corporate partnerships, technology and intellectual property licensing agreements, and OEM relationships and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources. He is member of Risk Committee and Disclosure Committee. Other current directorships include China Stem Cells Ltd (2010-present); Nanomix Inc. (2014-present) and One BioMed PTE Ltd (2021-present).